You just read:

Stealth BioTherapeutics Presents Phase 2 Data From MMPOWER-2 Continuation Trial Supporting Phase 3 Development of Elamipretide in Primary Mitochondrial Myopathy

News provided by

Stealth BioTherapeutics

Jun 29, 2017, 11:30 ET